MS
Sanofi shares results from phase 2 trial for frexalimab in MS treatment
July 1, 2024Research and Development MS, Neurology, Sanofi, multiple sclerosis
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …
FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS
August 25, 2023Medical Communications FDA, MS, Neurology, Sandoz
Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …
Genentech shares results from phase 3 trial for MS treatment
July 13, 2023Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial
Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …
FDA approves new IM administration route for Biogen’s MS drug Plegridy
February 2, 2021Manufacturing and Production Biogen, MS
The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …
Roche to start new trials of Ocrevus to defend multiple sclerosis franchise
September 9, 2020Research and Development MS, MS drug, Roche
Roche is to begin expanding trials of Ocrevus in multiple sclerosis (MS) patients to defend its MS franchise from its …
Sanofi to buy Principia Biopharma for $3.4 billion
August 17, 2020Sales and Marketing MS, Sanofi
Sanofi is set to buy California based Principia Biopharma in a deal that is worth $3.4 billion. This deal means …
Novartis releases results of MS drug trials weeks ahead of FDA verdict
May 28, 2020Business Services MS, Novartis
Novartis has revealed clinical trial data from testing its anti-CD20 leukameia drug Arzerra (ofatumumab) in patients with multiple sclerosis (MS). …
FDA approves MS drug for human trials
January 27, 2020Sales and Marketing MS, MS symptoms, MS treatment, Neuro, neurology
A drug that can make it easier to diagnose Multiple Sclerosis (MS) has been approved for its first human trials …
Multiple sclerosis market to be worth $32.9bn in 2028
December 11, 2019Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma
The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …
MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows
August 9, 2019Medical Communications MS, brain cancer, glioblastoma, oncology, pharma
The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …
MRI scans can help predict MS patient’s long term prognosis, 15 year study shows
July 25, 2019Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma
MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …
Top Ten most popular articles on Pharmafile.com this week!
April 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Genentech, Gilead, HIV, MS, Novartis, kidney disease, pharma
This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK …
Novartis’ new MS drug to cost $88,000 a year
March 27, 2019Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis
Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …
Drug slows brain shrinkage associated with progressive multiple sclerosis, study shows
August 30, 2018Research and Development MS, brain, ibudilast, neuroscience, research
The multiple sclerosis drug ibudilast, slowed brain shrinkages in patients with progressive MS, a study published in the New England …
Roche’s Ocrevus cleared for NHS use in relapsing-remitting MS
June 22, 2018Medical Communications, Sales and Marketing MS, NICE, UK, multiple sclerosis, pharma
Roche and multiple sclerosis (MS) patients across England and Wales are celebrating the news that healthcare watchdog NICE has recommended …
